National Prescription Drug Utilization Information System
The National Prescription Drug Utilization Information System (NPDUIS) is a research initiative established by federal, provincial, and territorial Ministers of Health in September 2001. It is a partnership between the PMPRB and the Canadian Institute for Health Information (CIHI).
Its purpose is to provide decision makers with critical information and intelligence on price, utilization and cost trends. This allows more comprehensive and accurate information on medicine use and sources of cost pressures. NPDUIS operates independently of the regulatory activities of the Board of the PMPRB.
Recent publications
CompassRx, 9th Edition
This edition of the report focuses on the 2021/22 fiscal year, with a retrospective look at recent trends.
Meds Entry Watch 7th Edition
The Meds Entry Watch report focuses on medicines approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada.
Meds Pipeline Monitor 2022
The MPM is a horizon scanning report that features a selection of new medicines undergoing clinical evaluation or in pre-registration.
Resources and information
NPDUIS Analytical Studies
The NPDUIS initiative publishes a variety of studies that provide Canadians with comprehensive information on drug pricing, utilization, and cost trends in Canada and internationally. These include annual publications, report series, focused research reports and presentations.
NPDUIS Research Agenda
Research priorities and methodologies for NPDUIS for the current and upcoming years are established with the guidance of the NPDUIS Advisory Committee and reflect the priorities of the participating jurisdictions.
NPDUIS Source Materials
NPDUIS analyses are developed using a range of publicly and commercially sourced databases.
The NPDUIS Database maintained by CIHI includes pan-Canadian prescription claims-level data, focusing primarily on publicly financed drug benefit programs.
NPDUIS Advisory Committee
The Advisory Committee is composed of representatives from Health Canada and public drug plans across the country. The Committee includes observers from other Canadian health agencies and organizations.
Page details
- Date modified: